OncoDefender-CRC, which measures the expression of colorectal cancer-specific genes, is a prognostic test capable of predicting the risk of recurrence in patients previously treated with surgical resection of a stage I/II colon cancer tumor or stage I rectal cancer tumor. The company will officially launch the test later this month, according to the news release.
Read the news release about OncoDefender-CRC.
Read other coverage about colorectal cancer prevention:
– ACG, ASGE React to NYTimes ‘Letter’ About Colonoscopy
– ACOG Urges OB/GYNs to Encourage CRC Screening in Female Patients
– University of Cincinnati Tests Cholesterol Drug to Prevent Recurrence of Colorectal Cancer
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
